Mexican fitness influencer, died after suffering a cardiac arrest while being anesthetized for a procedure of miraDry, a treatment that uses thermal energy to eliminate underarm sweat glands. The coroner reported that Mena's death was attributed to a combination of Clenbuterol and anesthesia. Performance-enhancing drug A common misconception about Clenbuterol is that it has anabolic properties, and can increase muscle mass when used in higher dosages. This claim has never been substantiated, and likely originated from equine research. A beta-2 agonist, Clenbuterol has been found to increase short-term work rate and cardiovascular output, and consequently, its anabolic effects in horses can be attributed to exercise output and increased caloric intake. Given its ability to increase basal metabolic rate, maximum heart rate, and exercise output, Clenbuterol has ergogenic properties more closely related to ephedrine or amphetamine. The notion that Clenbuterol is an anabolic agent likely originated from author and renowned authority on performance-enhancement Dan Duchaine. Duchaine popularized the drug in the bodybuilding community, and was the first to suggest the drug had muscle-building properties. Likewise, Duchaine erred in promoting the drug Gamma-hydroxybutyric acid (GHB) as an anabolic agent, and served time for the unlawful possession and distribution of the drug in the mid-1990s. As of 2011, the World Anti-Doping Agency (WADA) listed Clenbuterol as an anabolic agent, despite the fact there is no evidence to suggest this is the case. As a β2 sympathomimetic, clenbuterol has also been used as a performance-enhancing drug. A three-year suspension for taking clenbuterol kept sprinter Katrin Krabbe from competing in the 1992 Summer Olympics, and effectively ended her athletic career. In 2006, San Francisco Giants pitcher Guillermo Mota, while a member of the New York Mets, received a 50-game suspension after testing positive for clenbuterol. In 2012, MLB officials announced they were again suspending Mota for 100 games due a positive test for clenbuterol. American swimmer Jessica Hardy tested positive at the US trials in 2008. She was subject to a one-year suspension, having claimed she unknowingly took the drug in a contaminated food supplement. Former New York Mets clubhouse employee Kirk Radomski admitted in his plea deal to distributing clenbuterol to dozens of current and former Major League Baseball players and associates. After finishing fourth in the K-2 1000-m event at the 2008 Summer Olympics in Beijing, Polish sprint canoer Adam Seroczyński was disqualified for taking this drug, and Chinese cyclist Li Fuyu tested